Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models

Leuk Lymphoma. 2019 Dec;60(12):3067-3070. doi: 10.1080/10428194.2019.1617860. Epub 2019 Jun 17.

Authors

Lucile Astorgues-Xerri¹, Ramiro Vázquez², Elodie Odore³, Keyvan Rezai³, Carmen Kahatt¹, Sarah Mackenzie¹, Mohamed Bekradda¹, Marie-Magdelaine Coudé⁴, Herve Dombret⁴, Claude Gardin⁴, Francois Lokiec³, Eric Raymond⁵, Kay Noel⁶, Esteban Cvitkovic⁶, Patrice Herait⁶, Francesco Bertoni², María E Riveiro¹

Affiliations

¹ Oncology Therapeutic Development, Clichy, France.
² Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland.
³ RadioPharmacology Department, Curie Institute-Rene Huguenin Hospital, Saint Cloud, France.
⁴ Laboratoire de Transfert des Leucémies, Université Paris Diderot, Paris, France.
⁵ Medical Oncology Department, CHUV, Lausanne, Switzerland.
⁶ Oncoethix SA, Lucerne, Switzerland.

PMID: 31204545
DOI: 10.1080/10428194.2019.1617860

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acetanilides / pharmacology*
Animals
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects
Biomarkers, Tumor
Cell Cycle / drug effects
Cell Line, Tumor
Disease Models, Animal
Drug Synergism
Heterocyclic Compounds, 3-Ring / pharmacology*
Humans
Mice
Mutation
Proteins / antagonists & inhibitors*
Xenograft Model Antitumor Assays

Substances

Acetanilides
Antineoplastic Agents
Biomarkers, Tumor
Heterocyclic Compounds, 3-Ring
OTX015
Proteins
bromodomain and extra-terminal domain protein, human